pete_nash said:

CRP reduction on cardiovascular risk — this is the lab result that excites me most: Baseline hsCRP: 6.0 mg/L (high cardiovascular risk) Month 6 hsCRP:…

SUSTAIN-6 was the first CVOT to show cardiovascular benefit with semaglutide, relevant to cardiovascular risk. In 3,297 T2DM patients with high CV risk: MACE HR 0.74 (95% CI 0.58-0.95, p=0.02)[1].

Notable: the retinopathy signal in SUSTAIN-6 (HR 1.76) was subsequently attributed to rapid A1C reduction in patients with pre-existing retinopathy — not a direct drug effect. This has been confirmed in longer-term follow-up studies.

ZaraB_AL said:

Anti-inflammatory mechanisms of GLP-1 agonists and cardiovascular risk: beyond weight loss, GLP-1R activation directly suppresses NF-κB signaling,…

Thank you for spelling out the reasoning rather than just the conclusion. Printing the relevant bit and taking it with me.

pete_nash said:

CRP reduction on cardiovascular risk — this is the lab result that excites me most: Baseline hsCRP: 6.0 mg/L (high cardiovascular risk) Month 6 hsCRP:…

6 month update on cardiovascular risk: down 45 lbs, off blood pressure meds, A1C normalized. Genuinely life-changing.

chris_chi24 said:

My reason for being on this is cardiovascular rather than cosmetic, which puts me in a small minority in most of these threads.

Mendelian randomization evidence supporting GLP-1 pathway modulation for cardiovascular risk: genetic variants in the GLP1R gene region associated with lower BMI also show associations with reduced cardiovascular risk, confirming a causal pathway[1].

This "natural experiment" (people born with genetically higher GLP-1 signaling being leaner and healthier) provides orthogonal evidence supporting the pharmacological approach. When genetic epidemiology, clinical trials, and mechanistic studies all converge, confidence in the therapeutic approach is high.

Moderator note: a couple of off-topic posts removed. No action needed from anybody.